---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-283078"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:52:22.539568+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verrica Q3 revenue $14.3M (YCANTH $3.6M, license $10.7M); net loss narrows to $0.3M

## Summary
- Q3 net loss $0.3M ($0.03/sh) vs $22.9M loss ($4.88/sh) in Q3'24; non-GAAP net income $1.2M.
- YCANTH dispensed units 14,093 in Q3 (+4.9% sequentially); nine-month total 37,642 (+120% YoY).
- Received $10M milestone from Torii for Japan YCANTH approval; global Phase 3 for common warts started.
- FDA aligned on Phase 3 design for VP-315 in basal cell carcinoma; positive EMA feedback supports MAA filing.
- Cash $21.1M; sales force expanded to 45 reps, targeting 50 in 2026.

## SEC filing metadata
- accession: 0001193125-25-283078
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312525283078/0001193125-25-283078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312525283078/d99039d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-283078
- JSON: https://secwatch.observer/filing/0001193125-25-283078.json
- Plain text: https://secwatch.observer/filing/0001193125-25-283078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.